The effect of vildagliptin on endothelium-dependent vasodilatation. A double blind, cross-over study in type 2 diabetes. - Vildagliptin and vasodilatation

MC St Radboud0 个研究点目标入组 16 人开始时间: 2009年10月15日最近更新: 2022年5月9日

适应症

试验速览

暂无简介。

•The research population will consist of patients with type 2 diabetes of all ethnic backgrounds, both sexes and age 35-75 years.
•Inclusion criteria
•Type 2 diabetes
•Age 35-75 years
•Treatment with metformin monotherapy or metformin combination therapy
•HbA1c <8.0 %
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Renal disease defined as creatinine level > 130 umol/l
•Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range
•Current use of acetylsalicylic acid or vitamine K antagonists
•History of smoking within the past year
•History of or current abuse of drugs or alcohol
•History of heartfailure (NYHA class III or IV)
•Abnormalities on ECG that might interfere with current study protocol
•Pregnancy or breastfeeding
•Inability to understand the nature and extent of the trial and procedures required
•Presence of any medical condition that might interfere with the current study protocol
•Participation in a drug trial within 60 days prior to the first dose

发起方

MC St Radboud